Dr. Marc Grasso brings more than 25 years of public company, capital markets and investment banking expertise to the role
Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as its Chief Financial Officer. Dr. Grasso brings more than 25 years of public company, capital markets, and investment banking management experience to the role. He succeeds Ryan Jones, MBA, who will move to a strategic advisor role to ensure a seamless transition.
Health Technology Insights: Omeros Submits Narsoplimab MAA to EMA for TA-TMA Treatment
“We are excited to welcome Marc, an accomplished life-sciences leader with a proven track record working in capital markets and driving financial discipline and operational execution in maturing public companies,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “As we continue to accelerate our clinical development and commercialization efforts, Marc’s leadership will be instrumental in supporting our next phase of growth and advancing our mission to bring the transformative potential of CAR T-cell therapy to patients with autoimmune diseases. On behalf of the Kyverna leadership team, I’d also like to thank Ryan, one of Kyverna’s first employees, for the significant contributions he has made throughout his tenure with the Company.”
Most recently, Dr. Grasso served as CFO of Alector, Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, where he oversaw Financial Planning and Analysis, Investor Relations, Accounting, Information Technology and Facilities. Prior to Alector, Dr. Grasso held the position of CFO and Chief Business Officer of Kura Oncology. At these companies, Dr. Grasso was instrumental in optimizing capital allocation, strategic alliances, partnerships and licensing transactions.
Health Technology Insights: Lavior Pharma Appoints Daniel Kim as Vice President of Sales for Asia Pacific Market
Dr. Grasso has also held several leadership roles in the investment banking sector, including as Managing Director at Stifel, where he was responsible for building and managing the west coast life sciences and biotechnology investment banking business. He also held roles as Managing Director of Investment Banking in the Global Healthcare Group at UBS, focused on the biotechnology sector, and as Managing Director of Investment Banking at Leerink Swann, where he was instrumental in the west coast expansion of their franchise. Dr. Grasso joined Leerink from Morgan Stanley and held earlier positions in the global healthcare group of Credit Suisse First Boston and at Deutsche Banc Alex. Brown. During his Wall Street career, Dr. Grasso cultivated a strong network and deep understanding of the life sciences industry.
“I am thrilled to join Kyverna at this dynamic time and help accelerate the next critical phase of growth for the Company,” said Dr. Grasso. “I look forward to leveraging my experience to contribute to Kyverna’s goal of bringing the first CAR T-cell therapy for autoimmune disease to market and drive business and financial strategies that support the Company’s mission.”
Dr. Grasso received his medical degree from Johns Hopkins University School of Medicine, where he performed research in molecular oncology. He obtained a Bachelor of Arts degree in molecular biology with honors from Princeton University.
Health Technology Insights: Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
